Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 345 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: PSA Clear all
Not yet recruiting Phase 2 Interventional

Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

NCT07574541
View directory record Official record
Conditions
Adenocarcinoma, Prostate Cancer, Neoplasms, Carcinoma, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type
Interventions
TriAdeno vaccine, N-803
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 22, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

NCT01415960
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide acetate 22.5 mg depot, GP-Pharm SA
Drug
Lead sponsor
GP-Pharm
Industry
Eligibility
18 Years and older · Male only
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
25
States / cities
San Diego, California • Daytona Beach, Florida • Ocala, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jul 22, 2026, 4:06 PM EDT
Terminated Phase 2 Interventional Results available

Ipilimumab + Androgen Depravation Therapy in Prostate Cancer

NCT01377389
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ipilimumab, Leuprolide, Goserelin, Degarelix
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Jul 22, 2026, 4:06 PM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

NCT01531205
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androgen Ablation, Cabazitaxel, Salvage Therapy, Neoadjuvant Treatment - Hormonal Therapy, Neoadjuvant Treatment - Cabazitaxel
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Jul 22, 2026, 4:06 PM EDT
Completed No phase listed Observational

A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database

NCT05421442
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
38,396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Lawrenceville, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Jul 22, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)

NCT01307423
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Apremilast 20mg, Apremilast 30mg, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
30
States / cities
Phoenix, Arizona • Palm Desert, California • Doral, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Jul 22, 2026, 4:06 PM EDT
Recruiting Phase 3 Interventional

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

NCT06671483
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Zasocitinib, Active Comparator, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,088 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
51
States / cities
Chandler, Arizona • Phoenix, Arizona • Fountain Valley, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 22, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Results available

PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance

NCT02326805
View directory record Official record
Conditions
Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Placebo Administration, Rilimogene Galvacirepvec
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Male only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
7
States / cities
Los Angeles, California • Newport Beach, California • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Jul 22, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy

NCT00002874
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, radiation therapy, placebo
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Male only
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2022
U.S. locations
221
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 168 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Jul 22, 2026, 4:06 PM EDT
Recruiting No phase listed Observational

EDRN Prostate MRI Biomarker Study

NCT03784924
View directory record Official record
Conditions
PSA, Prostate Cancer
Interventions
MRI prostate
Diagnostic Test
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Male only
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 22, 2026, 4:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prostate Specific Antigen (PSA) and Acute Failure Modes Study of the PATH Woman's Condom and FC2 Female Condom

NCT01178840
View directory record Official record
Conditions
Birth Control
Interventions
WC then FC2, FC2 then WC
Device
Lead sponsor
CONRAD
Other
Eligibility
18 Years and older
Enrollment
505 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Jul 22, 2026, 4:06 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)

NCT00514917
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Docetaxel, Leuprolide, Bicalutamide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 3, 2013 · Synced Jul 22, 2026, 4:06 PM EDT
Not yet recruiting Not applicable Interventional

ExosomeDx in MRI-negative Men With High PSA

NCT06966089
View directory record Official record
Conditions
Prostate Cancer
Interventions
Urinary ExoDx test, Transrectal ultrasound-guided prostate biopsy, Transperineal 12-core prostate biopsy
Device · Diagnostic Test
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Male only
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2025 · Synced Jul 22, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Results available

Study of Acai Juice in Asymptomatic or Minimally Symptomatic Prostate Cancer Patients With Rising PSA

NCT01521949
View directory record Official record
Conditions
Prostate Cancer
Interventions
Acai Juice Product
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Jul 22, 2026, 4:06 PM EDT
Active, not recruiting No phase listed Observational

Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer

NCT03957252
View directory record Official record
Conditions
Prostate Cancer
Interventions
Blood test: ClarityDX Prostate
Diagnostic Test
Lead sponsor
Nanostics
Industry
Eligibility
40 Years to 75 Years · Male only
Enrollment
2,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Jul 22, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Results available

Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer

NCT02649855
View directory record Official record
Conditions
Prostate Cancer, Prostate Neoplasms, Neoplasms, Prostatic
Interventions
PROSTVAC-V, PROSTVAC-F, Docetaxel
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jul 22, 2026, 4:06 PM EDT
Active, not recruiting Phase 2 Interventional

Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer

NCT03471650
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-DCFPyL Injection
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jul 22, 2026, 4:06 PM EDT
Completed Not applicable Interventional Results available

Behavioral Economics Applications to Geriatrics Leveraging EHRs

NCT03704389
View directory record Official record
Conditions
Prostate Specific Antigen, Asymptomatic Bacteriuria, Type 2 Diabetes Mellitus
Interventions
Clinical decision support
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Jul 22, 2026, 4:06 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Marker Driven Selection of Patients for Prostate Biopsy and Management

NCT04240327
View directory record Official record
Conditions
PSA, Elevated PSA, Prostate Cancer
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
40 Years to 85 Years · Male only
Enrollment
289 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 22, 2026, 4:06 PM EDT
Withdrawn Phase 2 Interventional

Ciprofloxacin Compared to Placebo in Diagnosing Prostate Cancer in Patients Undergoing Prostate Biopsy

NCT02252978
View directory record Official record
Conditions
Prostate Cancer
Interventions
ciprofloxacin, placebo, quality-of-life assessment, laboratory biomarker analysis
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Salisbury, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Jul 22, 2026, 4:06 PM EDT
Completed Phase 2 Interventional

Chemotherapy, Hormone Therapy, and Surgery to Remove the Prostate Gland in Patients With High Risk Prostate Cancer

NCT00108290
View directory record Official record
Conditions
Prostate Cancer
Interventions
Chemotherapy
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 80 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 3, 2008 · Synced Jul 22, 2026, 4:06 PM EDT
Completed Not applicable Interventional

Effects of GCP on Prostate Cancer.

NCT00269555
View directory record Official record
Conditions
Prostate Cancer
Interventions
Genistein Combined Polysaccharide (GCP)
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
Male only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2010 · Synced Jul 22, 2026, 4:06 PM EDT
Completed No phase listed Observational

Follow-Up Study for Men Diagnosed With Prostate Cancer Through Participation in a Prostate Specific Antigen Screening Program

NCT00035217
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Results available

To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen

NCT00715078
View directory record Official record
Conditions
Prostate Cancer
Interventions
sipuleucel-T
Biological
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
12
States / cities
La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Jul 22, 2026, 4:06 PM EDT